S&P 500   4,447.30 (-0.18%)
DOW   34,951.28 (+0.44%)
QQQ   369.42 (-1.05%)
AAPL   145.05 (-1.27%)
MSFT   293.87 (-1.83%)
FB   351.02 (-0.55%)
GOOGL   2,821.72 (-0.79%)
TSLA   793.20 (+2.43%)
AMZN   3,373.97 (-1.50%)
NVDA   214.71 (-2.76%)
BABA   148.24 (+2.18%)
NIO   36.33 (+2.69%)
CGC   14.71 (+5.75%)
GE   106.06 (+2.18%)
MU   75.02 (+1.31%)
AMD   107.16 (+1.29%)
T   27.62 (+1.81%)
F   14.23 (+3.27%)
ACB   6.39 (+7.39%)
DIS   178.79 (+1.59%)
PFE   43.75 (-0.43%)
BA   226.24 (+2.19%)
BAC   43.34 (+2.85%)
S&P 500   4,447.30 (-0.18%)
DOW   34,951.28 (+0.44%)
QQQ   369.42 (-1.05%)
AAPL   145.05 (-1.27%)
MSFT   293.87 (-1.83%)
FB   351.02 (-0.55%)
GOOGL   2,821.72 (-0.79%)
TSLA   793.20 (+2.43%)
AMZN   3,373.97 (-1.50%)
NVDA   214.71 (-2.76%)
BABA   148.24 (+2.18%)
NIO   36.33 (+2.69%)
CGC   14.71 (+5.75%)
GE   106.06 (+2.18%)
MU   75.02 (+1.31%)
AMD   107.16 (+1.29%)
T   27.62 (+1.81%)
F   14.23 (+3.27%)
ACB   6.39 (+7.39%)
DIS   178.79 (+1.59%)
PFE   43.75 (-0.43%)
BA   226.24 (+2.19%)
BAC   43.34 (+2.85%)
S&P 500   4,447.30 (-0.18%)
DOW   34,951.28 (+0.44%)
QQQ   369.42 (-1.05%)
AAPL   145.05 (-1.27%)
MSFT   293.87 (-1.83%)
FB   351.02 (-0.55%)
GOOGL   2,821.72 (-0.79%)
TSLA   793.20 (+2.43%)
AMZN   3,373.97 (-1.50%)
NVDA   214.71 (-2.76%)
BABA   148.24 (+2.18%)
NIO   36.33 (+2.69%)
CGC   14.71 (+5.75%)
GE   106.06 (+2.18%)
MU   75.02 (+1.31%)
AMD   107.16 (+1.29%)
T   27.62 (+1.81%)
F   14.23 (+3.27%)
ACB   6.39 (+7.39%)
DIS   178.79 (+1.59%)
PFE   43.75 (-0.43%)
BA   226.24 (+2.19%)
BAC   43.34 (+2.85%)
S&P 500   4,447.30 (-0.18%)
DOW   34,951.28 (+0.44%)
QQQ   369.42 (-1.05%)
AAPL   145.05 (-1.27%)
MSFT   293.87 (-1.83%)
FB   351.02 (-0.55%)
GOOGL   2,821.72 (-0.79%)
TSLA   793.20 (+2.43%)
AMZN   3,373.97 (-1.50%)
NVDA   214.71 (-2.76%)
BABA   148.24 (+2.18%)
NIO   36.33 (+2.69%)
CGC   14.71 (+5.75%)
GE   106.06 (+2.18%)
MU   75.02 (+1.31%)
AMD   107.16 (+1.29%)
T   27.62 (+1.81%)
F   14.23 (+3.27%)
ACB   6.39 (+7.39%)
DIS   178.79 (+1.59%)
PFE   43.75 (-0.43%)
BA   226.24 (+2.19%)
BAC   43.34 (+2.85%)
NYSE:CTLT

Catalent Stock Forecast, Price & News

$136.63
-4.71 (-3.33 %)
(As of 09/27/2021 12:09 PM ET)
Add
Compare
Today's Range
$136.55
$140.71
50-Day Range
$110.84
$142.35
52-Week Range
$79.65
$142.64
Volume7,831 shs
Average Volume968,179 shs
Market Capitalization$23.33 billion
P/E Ratio44.22
Dividend YieldN/A
Beta1.43
30 days | 90 days | 365 days | Advanced Chart
Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.


Catalent logo

About Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets, and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy; formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. The Oral and Speciality Delivery segment consists of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment involves packaging, storage, distribution, and inventory management f

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

331st out of 1,352 stocks

Pharmaceutical Preparations Industry

154th out of 666 stocks

Analyst Opinion: 2.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Catalent (NYSE:CTLT) Frequently Asked Questions

Is Catalent a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalent stock.
View analyst ratings for Catalent
or view top-rated stocks.

What stocks does MarketBeat like better than Catalent?

Wall Street analysts have given Catalent a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Catalent wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Catalent
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) posted its quarterly earnings data on Sunday, August, 29th. The company reported $1.16 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.15. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.14 billion. Catalent had a net margin of 14.26% and a trailing twelve-month return on equity of 14.28%. The business's quarterly revenue was up 25.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 EPS.
View Catalent's earnings history
.

How has Catalent's stock price been impacted by COVID-19 (Coronavirus)?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTLT shares have increased by 198.1% and is now trading at $137.27.
View which stocks have been most impacted by COVID-19
.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2022 earnings guidance on Monday, September, 27th. The company provided earnings per share (EPS) guidance of $3.230-$3.550 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.340. The company issued revenue guidance of $4.30 billion-$4.50 billion, compared to the consensus revenue estimate of $4.33 billion.

What price target have analysts set for CTLT?

10 brokerages have issued 1-year target prices for Catalent's shares. Their forecasts range from $109.00 to $162.00. On average, they expect Catalent's share price to reach $140.80 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for Catalent
or view top-rated stocks among Wall Street analysts.

Who are Catalent's key executives?

Catalent's management team includes the following people:

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent CEO John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among Catalent's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.18%), Vanguard Group Inc. (10.76%), BlackRock Inc. (8.41%), State Street Corp (3.88%), Franklin Resources Inc. (3.17%) and Veritas Asset Management LLP (3.11%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano and Wetteny Joseph.
View institutional ownership trends for Catalent
.

Which institutional investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Thrivent Financial for Lutherans, Thrivent Financial for Lutherans, APG Asset Management N.V., Price T Rowe Associates Inc. MD, Baird Financial Group Inc., FMR LLC, and Franklin Resources Inc.. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano, and Wetteny Joseph.
View insider buying and selling activity for Catalent
or view top insider-selling stocks.

Which institutional investors are buying Catalent stock?

CTLT stock was bought by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Amundi, BlackRock Inc., State Street Corp, JPMorgan Chase & Co., TimesSquare Capital Management LLC, Citigroup Inc., and Marshall Wace LLP.
View insider buying and selling activity for Catalent
or or view top insider-buying stocks.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $137.27.

How much money does Catalent make?

Catalent has a market capitalization of $23.44 billion and generates $4.00 billion in revenue each year. The company earns $529 million in net income (profit) each year or $2.80 on an earnings per share basis.

How many employees does Catalent have?

Catalent employs 17,300 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

Where are Catalent's headquarters?

Catalent is headquartered at 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at (732) 537-6200 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.